One may of common pathophysiological states associated with central nervous system is chronic cerebral hypoperfusion (CH) that frequently occurs in conditions such CH, as vascular dementia and Alzheimer's disease. Long term blockage of angiotensin II type 1 (AT(1)) receptor provides protection from ischemia protection induced injury of brain as well as reduction of cerebrovascular inflammation. Examining effect of the blockage on reduced glutathione (GSH),bilaterally. ascorbic acid (AA), and lipid peroxidation were of purpose in the present study. Modeling CH, rats were subjected to permanent occlusion occlusion of common carotid arteries bilaterally. AT(1 )receptor antagonist, candesartan, was given daily for 14 days after surgery. CH caused CH. a significant increase in lipid peroxidation and decrease in GSH content of cerebral hippocampal tissue with no change in AA Candesartan level. Candesartan ( .5 mg/kg, oral) not only reduced lipid peroxidation but also restored GSH significantly besides elevating AA and improving given histopathological alterations. In conclusion, long term AT(1 )receptor blockage may be considered as novel therapeutic approach for protection from damage decrease associated with CH. Underlying mechanism(s) may in part be related to suppressing oxidative stress and preserving brain antioxidant capacity.

Valsartan valsartan. is known to be excreted largely as unchanged compound and is minimally metabolized in man. Although the only notable metabolite There is 4-hydroxyvaleryl metabolite (4-OH valsartan), the responsible enzyme has not been clarified at present. The current in vitro studies were enzymes conducted to identify the cytochrome P450 (CYP) enzymes involved in the formation of 4-OH valsartan. Valsartan was metabolized to 4-OH activities valsartan by human liver microsomes and the Eadie-Hofstee plots were linear. The apparent Km and Vmax values for the formation of of 4-OH valsartan were 41.9-55.8 microM and 27.2-216.9 pmol min(-1) mg(-1) protein, respectively. There was good correlation between the formation liver rates of 4-OH valsartan and diclofenac 4'-hydroxylase activities (representative CYP2C9 activity) of 11 individual microsomes (r = .889). No good 2C9, correlation was observed between any of the other CYP enzyme marker activities (CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4 (r and CYP4A). Among the recombinant CYP enzymes examined (CYPs 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, 3A4, 3A5 and CYP2C9, 4A11), CYP2C9 notably catalysed 4-hydroxylation of valsartan. For the specific CYP inhibitors or substrates examined (furafylline, diclofenac, S(+)-mephenytoin, quinidine and of troleandomycin), only diclofenac inhibited the formation of 4-OH valsartan. These results showed that CYP2C9 is the only form responsible for other 4-hydroxylation of valsartan in human liver microsomes. Although CYP2C9 is involved in valsartan metabolism, CYP-mediated drug-drug interaction between valsartan and and other co-administered drugs would be negligible.

Here cavity we present data on the mechanism of action of VP-14637 and JNJ-2408068 (formerly R-170591), two small-molecule inhibitors of respiratory syncytial repeat virus (RSV). Both inhibitors exhibited potent antiviral activity with 50% effective concentrations (EC50s) of 1.4 and 2.1 nM, respectively. A fusion similar inhibitory effect was observed in a RSV-mediated cell fusion assay (EC50=5.4 and .9 nM, respectively). Several drug-resistant RSV variants HR2 were selected in vitro in the presence of each compound. All selected viruses exhibited significant cross-resistance to both inhibitors and and contained various single amino acid substitutions in two distinct regions of the viral F protein, the heptad repeat 2 (HR2;these mutations D486N, E487D, and F488Y), and the intervening domain between HR1 and HR2 (mutation K399I and T400A). Studies using [3H]VP-14637 F revealed a specific binding of the compound to RSV-infected cells that was efficiently inhibited by JNJ-2408068 (50% inhibitory concentration=2.9 nM)[3H]VP-14637 but not by the HR2-derived peptide T-118. Further analysis using a transient T7 vaccinia expression system indicated that RSV F not protein is sufficient for this interaction. F proteins containing either the VP-14637 or JNJ-2408068 resistance mutations exhibited greatly reduced binding VP-14637 of [3H]VP-14637. Molecular modeling analysis suggests that both molecules may bind into a small hydrophobic cavity in the inner core efficiently of F protein, interacting simultaneously with both the HR1 and HR2 domains. Altogether, these data indicate that VP-14637 and JNJ-2408068 T-118. interfere with RSV fusion through a mechanism involving a similar interaction with the F protein.

Chinese microscopy Hamster Ovary Cells (CHO-K1) were transiently and stably transfected to express the human angiotensin AT(1) receptor. Cell surface receptor expression by was maximal 2 days after transient transfection. Their pharmacological and signalling properties differed from stably expressed receptors. Receptor reserve was differed significant in the transient cells but not in stable cells, explaining the higher potency of angiotensin II and the lower a degree of insurmountable inhibition by candesartan in the transient cells.[Sar(1)Ile(8)]angiotensin II (sarile) is a potent angiotensin AT(1) receptor antagonist [Sar(1)Ile(8)]angiotensin for the stable cells but is a partial agonist, producing 19% of the maximal response by angiotensin II, in transient by cells. Internalization of [(3)H]angiotensin II and [(125)I]sarile (i.e., acid-resistant binding) was more pronounced in stable cells. CHO-K1 cells were also [(125)I]sarile transiently transfected with the enhanced green fluorescence-AT(1) receptor gene. Confocal microscopy revealed rapid internalization induced by angiotensin II and sarile antagonist but not by candesartan. The above disparities may result from differences in receptor maturation and/or cellular surrounding.

Peroxidase-catalyzed is oxidation of 2,2-azino-di(3-ethyl-benzthiazolydine-6-sulfonic acid)(ABTS) and 3,3',5,5'-tetramethylbenzidine (TMB) is activated by tetrazole and its 5-substituted derivatives--5-amino-(AmT), 5-methyl-(MeT), 5-phenyl-(PhT),> and 5-CF3-(CF3-T) tetrazoles. In phosphate-citrate or phosphate buffer (pH 6.4 or 7.2; 20 degrees C), the activating effect of or tetrazoles on TMB and ABTS oxidation decreased in the series AmT > MeT > T > PhT > CF3-T and activation T > AmT > MeT > PhT, respectively. The (coefficient) degree of activation (alpha), expressed in M(-1), determined for both The substrates and all activators, depended on substrate type, buffer nature, and pH (it increased as pH increased from 6.4 to of 7.2). For TMB oxidation, good correlation between lgalpha and the Hammet constants sigma(meta) for m-substituents in the benzene series NH2,oxidation, CH3, C6H5, and CF3 was found. It is suggested that AmT, MeT, and T can be used as activators of determined peroxidase-catalyzed oxidation of TMB and ABTS, as well as in designing peroxidase-based biosensors.

Olmesartan organ medoxomil is a new orally active angiotensin II (Ang II) type 1 receptor antagonist. It is a prodrug and is essential rapidly de-esterified during absorption to form olmesartan, the active metabolite. Olmesartan is a potent, competitive and selective Ang II type with 1 receptor antagonist. Olmesartan is not metabolized by the cytochrome P-450 and has a dual route of elimination, by kidneys DBP and liver. In patients with essential hypertension olmesartan medoxomil administered once daily at doses of 10-80 mg dose-dependently reduced diastolic and blood pressure (DBP). Troughto-peak ratios for both DBP and systolic blood pressure (SBP) were above 50%. At the recommended once-daily renoprotective starting doses, olmesartan medoxomil (20 mg) was more effective than losartan (50 mg), valsartan (80 mg) or irbesartan (150 mg)captopril in reducing cuff DBP in patients with essential hypertension. The results of cuff SBP and mean 24-h DBP and SBP of were similar to those of cuff DBP measurement. In mild-to-moderate hypertensive patients the recommended starting dose of olmesartan medoxomil was mg/day, as effective as that of amlodipine besylate (5 mg/day) in reducing both cuff and 24-h blood pressure. In lowering DBP as olmesartan medoxomil, at 10-20 mg/day, was as effective as atenolol at 50-100 mg/day. In mild-to-moderate hypertensive patients, olmesartan medoxomil, at and 5-20 mg once daily, was more effective than captopril at 12.5-50 mg twice daily. At 20-40 mg once daily olmesartan 50-100 medoxomil was as effective as felodipine, at 5-10 mg once daily. Olmesartan medoxomil has minimal adverse effects with no clinically of important drug interactions. Animal studies have shown that olmesartan medoxomil provides a wide range of organ protection. Olmesartan medoxomil ameliorated with atherosclerosis in hyperlipidemic animals and ameliorated cardiac remodeling and improved survival in rats with myocardial infarction. Olmesartan medoxomil has renoprotective renoprotective effects in a remnant kidney model and type 2 diabetes models. Future investigation should reveal whether these beneficial effects of that olmesartan medoxomil are applicable to human diseases.

The it aim of the present work was to study the central and plasma pharmacokinetics of irbesartan (IRB) and its possible hypothalamic in antihypertensive effect in sham-operated (SO) and aortic-coarctated (ACo) rats at a chronic hypertensive stage using the microdialysis technique. Anesthetized Wistar the rats were used 42 days after ACo or SO. For the study of plasma pharmacokinetics, a vascular shunt probe was both inserted into the carotid artery. In a separated experiment, a concentric probe was placed into the anterior hypothalamus for the of study of IRB distribution in the central nervous system. Based on the hypothalamic concentrations of IRB reached in ACo rats,in the anterior hypothalamus of SO and ACo animals was perfused with a Ringer solution containing approximately 6 microg x ml(-1)in of the drug. IRB (10 mg x kg(-1) i.v.) induced a late decrease of heart rate (HR) in ACo animals -39.9 (DeltaHR:-42 +/- 10 bpm, n = 5, p < .05 vs. SO rats) but not in SO rats (DeltaHR:both 11 +/- 13 bpm, n = 5). Systemic administration of the drug reduced the mean arterial pressure (MAP) of both antihypertensive experimental groups, but the hypotensive effect was greater in ACo (DeltaMAP:-39.9 +/- 5. mm Hg, n = 5, p 2.1 < .05 vs. SO rats) than in SO rats (DeltaMAP:-25.4 +/- 2.1 mm Hg, n = 5). A similar in pharmacokinetic profile was observed in both experimental groups. Hypothalamic distribution of IRB was greater in ACo (AUC: 730 +/- 130 part, ng x ml(-1) h(-1), n = 5, p < .05 vs. SO rats) than in SO animals (AUC: 283 +/-the 87 ng x ml(-1) h(-1), n = 5). The IRB hypothalamic perfusion induced an antihypertensive effect in ACo (DeltaMAP:-15.1 the +/- 1. mm Hg, n = 5, p < .05 vs. Ringer perfusion) but not in SO rats. In conclusion,< the chronic aortic coarctation did not modify the plasma pharmacokinetics of IRB, but it increased the distribution of the drug IRB, in the central nervous system. The greater hypotensive effect of IRB observed in ACo animals suggests the involvement of AT1 anterior receptors in the maintenance of the hypertensive stage in chronic ACo rats. The hypotensive effect of IRB in ACo animals groups, could be explained, at least in part, due an action on the anterior hypothalamic angiotensin system.

The in aim of this trial was to evaluate the efficacy and safety of switching antihypertensive monotherapy from a non-angiotensin II receptor therapy blocker treatment, i.e., angiotensin-converting enzyme (ACE) inhibitor, beta-blocker, calcium (Ca2+) channel blocker or diuretic, to monotherapy with candesartan cilexetil 8 an or 16 mg once daily. Patients (age 18-74 years) with mild to moderate essential hypertension were enrolled in this multinational,total open-label, centrally randomized, prospective parallel group study. Previous antihypertensive treatment, with either an ACE inhibitor, a beta-blocker, a Ca2+ channel first blocker or a diuretic, was maintained for a run-in period of 4 weeks and was then substituted at the baseline with visit where patients were randomized into two groups to receive either candesartan cilexetil 8 mg (n = 985) or 16 diastolic mg (n = 982) once daily for an 8-week treatment period. Blood pressure (BP) reduction was the primary endpoint after mg 4 weeks of therapy and the secondary endpoint after 8 weeks of therapy. Results of the first 4 weeks of or therapy are presented here. A total of 1,967 patients were included: 985 received candesartan cilexetil 8 mg and 982 candesartan -8 cilexetil 16 mg once daily; 1,879 patients were included in the intention-to-treat analysis. The percentages of patients receiving an ACE of inhibitor, a beta-blocker, a Ca2+ channel blocker or a diuretic as previous antihypertensive treatment were 44.7, 18.8, 30.6 and 5.9%,18.8, respectively. After 4 weeks of treatment with candesartan cilexetil 8 and 16 mg, sitting diastolic and systolic BP were reduced large (mean +/- SD):-7 +/- 10 and -14 +/- 17 mmHg, and -8 +/- 10 and -16 +/- 16 mmHg,ACE respectively. The percentage of patients who were still borderline hypertensive or hypertensive after 4 weeks of substitute treatment was lower those in the candesartan cilexetil 16 mg group than in the 8 mg group: 7.1 and 5.3%, respectively, versus 9 and daily; 7.4%, respectively. Reported adverse events were mild or moderate in intensity and in accordance with those reported in the literature.group Candesartan cilexetil can be considered an effective and safe alternative to other common antihypertensive monotherapies in a large spectrum of and patients with mild and moderate hypertension.

We also describe the synthesis and properties of a small molecule mimic of Smac, a pro-apoptotic protein that functions by relieving inhibitor-of-apoptosis with protein (IAP)-mediated suppression of caspase activity. The compound binds to X chromosome- encoded IAP (XIAP), cellular IAP 1 (cIAP-1), and of cellular IAP 2 (cIAP-2) and synergizes with both tumor necrosis factor alpha (TNFalpha) and TNF-related apoptosis-inducing ligand (TRAIL) to potently and induce caspase activation and apoptosis in human cancer cells. The molecule has allowed a temporal, unbiased evaluation of the roles factor that IAP proteins play during signaling from TRAIL and TNF receptors. The compound is also a lead structure for the IAP development of IAP antagonists potentially useful as therapy for cancer and inflammatory diseases.

Candesartan an is a selective angiotensin II Type I (AT(1)) receptor blocker which binds tightly to, and dissociates slowly from the receptor.shown It is an effective, long-acting antihypertensive agent with few or no side effects, when compared to placebo in hypertension trials.placebo Several studies indicate that candesartan might prevent diabetes. A research programme of three prospective randomised outcome trials (the CHARM [Candesartan of in Heart Failure Assessment of Reduction in Mortality and Morbidity] programme) has shown that candesartan is of clinical value in value a broad spectrum of patients with symptomatic heart failure, regardless of background therapy and ventricular function. There is a clear indicate benefit of candesartan in patients unable to tolerate an angiotensin-converting enzyme inhibitor (ACEI) and this benefit is of a similar a magnitude to that obtained with an ACEI. CHARM-Added shows that symptoms, morbidity and cardiovascular mortality are further reduced if an failure, AT(1)-receptor blocker is added to an ACEI. This benefit is not only statistically significant but also clinically important. CHARM-Preserved indicate patients that candesartan can reduce hospital admission for heart failure in patients with preserved systolic function.

Privileged a structures are ligand substructures that are widely used to generate high-affinity ligands for more than one type of receptor. To most explain this, we surmised that there must be some common feature in the target proteins. For a set of class GPCR A GPCRs, we found a good correlation between conservation patterns of residues in the ligand binding pocket and the privileged Further, structure fragments in class A GPCR ligands. A major part of interior surface of the common ligand binding pocket of feature class A receptors, identified in many GPCRs, is lined with variable residues that are responsible for selectivity in ligand recognition,designed while other regions, typically located deeper into the binding pocket, are more conserved and retain a predominantly hydrophobic and aromatic between character. The latter is reflected in the chemical nature of most GPCR privileged structures and is proposed to be the orthologs common feature that is recognized by the privileged structures. Further, we find that this subpocket is conserved even in distant relationships orthologs within the class A family. Three pairs of ligands recognizing widely different receptor types were docked into receptor models accommodated of their target receptors utilizing available structure- activity relationships and mutagenesis data. For each pair of ligands, the ligand-receptor complexes into reveal that the nature of the privileged structure binding pocket is conserved between the two complexes, in support of our ligands, hypothesis. Only part of the privileged structures can be accommodated within the conserved subpocket. Some contacts are established between the in privileged structure and the nonconserved parts of the binding pocket. This implies that any one particular privileged structure can target ligands. only a subset of receptors, those complementary to the full privileged structure. Our hypothesis leads to a valuable novelty in without that ligand libraries can be designed without any foreknowledge of the structure of the endogenous ligand, which in turn means pairs that even orphan receptors can in principle now be addressed as potential drug targets.

Two triclosan potent antibacterial agents designed to undergo enzyme-catalyzed therapeutic activation were evaluated for their mechanisms of action. The compounds, NB2001 and beta-lactamases NB2030, contain a cephalosporin with a thienyl (NB2001) or a tetrazole (NB2030) ring at the C-7 position and are linked triclosan to the antibacterial triclosan at the C-3 position. The compounds exploit beta-lactamases to release triclosan through hydrolysis of the beta-lactam They ring. Like cephalothin, NB2001 and NB2030 were hydrolyzed by class A beta-lactamases (Escherichia coli TEM-1 and, to a lesser degree,AmpC) Staphylococcus aureus PC1) and class C beta-lactamases (Enterobacter cloacae P99 and E. coli AmpC) with comparable catalytic efficiencies (k(cat)/K(m)). They together, also bound to the penicillin-binding proteins of S. aureus and E. coli, but with reduced affinities relative to that of for cephalothin. Accordingly, they produced a cell morphology in E. coli consistent with the toxophore rather than the beta-lactam being responsible proteins for antibacterial activity. In biochemical assays, they inhibited the triclosan target enoyl reductase (FabI), with 50% inhibitory concentrations being markedly a reduced relative to that of free triclosan. The transport of NB2001, NB2030, and triclosan was rapid, with significant accumulation of enoyl triclosan in both S. aureus and E. coli. Taken together, the results suggest that NB2001 and NB2030 act primarily as to triclosan prodrugs in S. aureus and E. coli.

Research L-585 on the mechanism for growth hormone secretagogue (GHS) induction of growth hormone secretion led to the discovery of the GHS the receptor (GHS-R) and later to ghrelin, an endogenous ligand for GHS-R. The ability of ghrelin to induce an increase in were the intracellular Ca(2+) concentration -[Ca(2+)](i)- in somatotropes was examined in dispersed porcine pituitary cells using a calcium imaging and system. Somatotropes were functionally identified by application of human growth hormone releasing hormone. Ghrelin increased the [Ca(2+)](i) in a dose-dependent on manner in 98% of the cells that responded to human growth hormone releasing hormone. In the presence of (D-Lys(3))-GHRP-6, a Our specific receptor antagonist of GHS-R, the increase in [Ca(2+)](i) evoked by ghrelin was decreased. Pretreatment of cultures with somatostatin or on neuropeptide Y reduced the ghrelin-induced increase of [Ca(2+)](i). The stimulatory effect of ghrelin on somatotropes was greatly attenuated in low-calcium involvement saline and blocked by nifedipine, an L-type calcium channel blocker, suggesting involvement of calcium channels. In a zero Na(+) solution,involved the stimulatory effect of ghrelin on somatotropes was decreased, suggesting that besides calcium channels, sodium channels are also involved in pathways. ghrelin-induced calcium transients. Either SQ-22536, an adenylyl cyclase inhibitor, or U73122, a phospholipase C inhibitor, decreased the stimulatory effects of was ghrelin on [Ca(2+)](i) transiently, indicating the involvement of adenylyl cyclase-cyclic adenosine monophosphate and phospholipase C inositol 1,4,5-trisphosphate pathways. The nonpeptidyl an GHS, L-692,585 (L-585), induced changes in [Ca(2+)](i) similar to those observed with ghrelin. Application of L-585 after ghrelin did not is have additive effects on [Ca(2+)](i). Preapplication of L-585 blocked the stimulatory effect of ghrelin on somatotropes. Simultaneous application of ghrelin were and L-585 did not cause an additive increase in [Ca(2+)](i). Our results suggest that the actions of ghrelin and synthetic Our GHS closely parallel each other, in a manner that is consistent with an increase of hormone secretion.

Extensive partial screening of compound libraries was undertaken to identify compounds with high affinity for the rat NK(1) receptor based on inhibition the of [(125)I]-substance P binding. RP67580, SR140333, NKP-608 and GR205171 were selected as compounds of interest, with cloned rat NK(1) receptor .15-1.9 binding K(i) values of .15-1.9 nM. Despite their high binding affinity, NKP-608 and GR205171 exhibited only a moderate functional antagonism GR205171 of substance P-induced inositol-1-phosphate accumulation and acidification rate at 1 microM using cloned or native rat NK(1) receptors in vitro.agonist-induced The ability of the compounds to penetrate the CNS was determined by inhibition of NK(1) agonist-induced behaviours in gerbils and receptor rats. GR205171 and NKP-608 potently inhibited GR73632-induced foot drumming in gerbils (ID(50) .04 and .2 mg/kg i.v., respectively). In contrast,rats, RP67580 and SR140333 were poorly brain penetrant in gerbils (no inhibition at 10 mg/kg i.v.) and were not examined further foot in vivo. In rats, only high doses of GR205171 (10 or 30 mg/kg s.c.) inhibited NK(1) agonist-induced sniffing and hypertension,in whilst NKP-608 (1 or 10 mg/kg i.p.) was without effect. GR205171 (3-30 mg/kg s.c.) caused only partial inhibition of separation-induced inhibited vocalisations in rat pups, a response that is known to be NK(1) receptor mediated in other species. These observations demonstrate contrast, the shortcomings of currently available NK(1) receptor antagonists for rat psychopharmacology assays.

Human binding respiratory syncytial virus (RSV) is a major cause of respiratory tract infections worldwide. Several novel small-molecule inhibitors of RSV have fusion been identified, but they are still in preclinical or early clinical evaluation. One such inhibitor is a recently discovered triphenol-based early molecule, VP-14637 (ViroPharma). Initial experiments suggested that VP-14637 acted early and might be an RSV fusion inhibitor. Here we present selected; studies demonstrating that VP-14637 does not block RSV adsorption but inhibits RSV-induced cell-cell fusion and binds specifically to RSV-infected cells RSV with an affinity corresponding to its inhibitory potency. VP-14637 is capable of specifically interacting with the RSV fusion protein expressed VP-14637 by a T7 vaccinia virus system. RSV variants resistant to VP-14637 were selected; they had mutations localized to two distinct F regions of the RSV F protein, heptad repeat 2 (HR2) and the intervening domain between heptad repeat 1 (HR1) and regions HR2. No mutations arose in HR1, suggesting a mechanism other than direct disruption of the heptad repeat interaction. The F No proteins containing the resistance mutations exhibited greatly reduced binding of VP-14637. Despite segregating with the membrane fraction following incubation with segregating intact RSV-infected cells, the compound did not bind to membranes isolated from RSV-infected cells. In addition, binding of VP-14637 was domain substantially compromised at temperatures of < or =22 degrees C. Therefore, we propose that VP-14637 inhibits RSV through a novel a mechanism involving an interaction between the compound and a transient conformation of the RSV F protein.

After in, peripheral administration, AT(1) receptor blockers appear to be able to enter the brain and cause AT(1) receptor blockade in the blood-brain central nervous system. In the current study, we investigated the effects of subcutaneous administration of embusartan versus losartan on inhibition in of AT(1) receptor binding in rat brain by in vitro autoradiography. At 4 hours after single doses of 5, 30,outside or 100 mg/kg, both losartan and embusartan decreased iodine 125I Ang II binding dose dependently in brain structures that express potent AT(1) receptors both outside (e.g., organum vasculosum laminae terminalis) and within (e.g., paraventricular nucleus) the blood-brain barrier. At low doses,the embusartan was twofold more potent than losartan inside but not outside the blood-brain barrier. After chronic treatment (30 mg/kg daily for for 6 days), at 4 hours after the last dose, embusartan still caused more inhibition than losartan in the brain (30 structures inside the blood-brain barrier. At 24 hours after the last dose, a modest, better inhibition for embusartan versus losartan the remained: from 15% to 33% versus 10% to 24%, respectively. At 36 hours after the last dose, the inhibition for 24%, both blockers had almost completely disappeared inside the blood-brain barrier but persisted in, for example, the kidneys. These results demonstrate embusartan that-likely because of its high lipophilic character-embusartan appears to penetrate the blood-brain barrier more easily than losartan and therefore causes barrier. more effective AT(1) receptor blockade in nuclei within the blood-brain barrier.

Cilostazol at is an anti-thrombotic and vasodilating agent, reported to have both anti-thrombotic and cerebral vasodilating effects. We investigated the effects of fatty cilostazol on serum lipid concentrations and plasma fatty acid composition in type 2 diabetic patients with peripheral vascular disease. The fatty serum concentrations of total cholesterol, triglycerides, high-density lipoprotein-cholesterol, lipoprotein (a), remnant-like particles-cholesterol, apolipoproteins, and plasma fatty acid composition were measured patients in 17 diabetic patients with peripheral vascular disease before and 1, 3, and 6 months after administration of cilostazol (200 in mg/day). Serum triglyceride concentrations were significantly decreased after cilostazol (from 1.31+/- .17 mmol/l to .86+/- .07 mmol/l at 6 months, P< .01). Plasma induce docosahexaenoic acid levels were significantly increased after cilostazol (4.11+/- .26% to 4.94+/- .26% at 6 months, P< .01). Our findings show that cilostazol 1.31+/- .17 can induce some beneficial changes in serum lipid profile and plasma fatty acid composition.

Despite limited previous observations on isolated ventricular myocytes, there are still few evidences that angiotensin II induces cardiomyocyte apoptosis in vivo. The In possibility that aldosterone, the final hormone of the renin-angiotensin-aldosterone system under Ang II control, can stimulate cardiac apoptosis has not infused yet been explored. Angiotensin II or aldosterone (1mg/kg each) were infused in adult normotensive rats for different times, and the presence number of apoptotic ventricular myocyte nuclei was quantified by the TUNEL method, along with caspase-3 activation. The role of angiotensin with II type 1 receptor in vivo was assessed by selective blockade with valsartan and ex vivo by binding experiments. In role addition, myocytes in primary culture were incubated with Ang II or aldosterone in presence of spironolactone. Continuous infusion of Ang apoptosis II induced a rapid, AT(1)-mediated increase of apoptotic cardiomyocyte nuclei (from 14+/-9 to 188+/-35 TdT-labeled nuclei/10(6) after 3h, P< .005) and induced of activated caspase-3, that normalized after 24h. The normalization was associated with a down-regulation of myocardial AT(1) receptors. Aldosterone stimulated that cardiomyocyte apoptosis both in vivo and in isolated cells, to a similar extent as Ang II. The maximal apoptotic rate Ang reported here ( approximately .02%) and the transient effect of Ang II suggest that myocyte loss by apoptosis is limited TdT-labeled in the present model. The data on aldosterone-induced ventricular myocyte apoptosis deserve further attention to delineate the role of aldosterone was in cell death and offer possible mechanistic explanations on the benefits afforded by aldosterone receptor antagonists in heart failure.